FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E MutationGeoffrey Kim, Richard Pazdur, Yang‐Min Ning et al.|Clinical Cancer Research|2014Cited by 215